Free Trial
→ A weekly dividend fund holding Nvidia and Palantir (From Investors Alley) (Ad)tc pixel
OTCMKTS:OPHLF

Ono Pharmaceutical Earnings Date & Estimates

Ono Pharmaceutical logo
$14.95 0.00 (0.00%)
As of 10/9/2026

Ono Pharmaceutical is expected to report earnings on Wednesday, October 28, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Ono Pharmaceutical

Ono Pharmaceutical is expected to post earnings of $0.26 per share on revenue of $726.96 million. In the same quarter a year earlier Ono Pharmaceutical reported $0.3225 per share on revenue of $876.10 million. Ono Pharmaceutical last reported on February 2, 2026, posting $0.40 per share and beating the $0.2888 consensus estimate. Ono Pharmaceutical has beaten the consensus EPS estimate in 3 of its last 5 quarters.

Consensus Estimates

Consensus EPS
$0.26
Expected Revenue
$726.96 million
Prior-Year EPS
$0.3225
Prior-Year Revenue
$876.10 million
Expected EPS Growth
-19.4%
Expected Revenue Growth
-17.0%

Recent Track Record

Last Reported
Q3 2026
Last Quarter EPS
$0.40 (Beat by +$0.1112)
Last Quarter Revenue
$892.70 million
EPS Beat Rate
3 of last 5 quarters

Prepare for the Earnings Call

Ono Pharmaceutical Earnings FAQ

Ono Pharmaceutical (OTCMKTS:OPHLF) is estimated to report earnings on Wednesday, October 28, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Ono Pharmaceutical to post earnings of $0.26 per share for the quarter.

The consensus revenue estimate for Ono Pharmaceutical is $726.96 million for the quarter.

Ono Pharmaceutical Earnings Headlines

Biohaven licenses IgG degrader portfolio to Japan’s Ono
October 8 at 6:20 PM  |  seekingalpha.comhttps://seekingalpha.com/news/4651387-biohaven-licenses-igg-degrader-portfolio-to-japans-ono
Ono’s New Pediatric Cancer Trial Signals Steady Pipeline Progress for O.P.H.L.F Investors
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/onos-new-pediatric-cancer-trial-signals-steady-pipeline-progress-for-o-p-h-l-f-investors?utm_source=marketbeat.com&utm_medium=referral
No. 1 stock to cash in on the death of iPhone
Analyst Josh Baylin, who warned Congress about smartphones years before the iPhone launched, says the world's richest man may be building an iPhone rival he calls Starphone. Baylin points to FCC rulings, two trademarks filed the same day, multibillion-dollar spectrum deals, chip partnerships, and a string of posts from Elon Musk as evidence pointing to one conclusion. See the full research and the stock Baylin is watching now.tc pixel
October 10 at 1:00 AM  |  Stansberry Research (Ad)
Ono Pharmaceutical Co. (OPHLF) Soars 13.9%: Is Further Upside Left in the Stock?
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/ono-pharmaceutical-co-ophlf-soars-110000378.html
Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases
September 1, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260901390619/en/ono-pharma-enters-into-a-drug-discovery-partnership-with-aitia-in-neurological-diseases/
Ono Pharma’s New Cancer Trial Adds Early-Stage Upside—and Risk—for OPHLF Investors
August 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ono-pharmas-new-cancer-trial-adds-early-stage-upside-and-risk-for-ophlf-investors?utm_source=marketbeat.com&utm_medium=referral
See More Ono Pharmaceutical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ono Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ono Pharmaceutical and other key companies, straight to your email.

About Ono Pharmaceutical

Ono Pharmaceutical (OTCMKTS:OPHLF) Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and commercialization of prescription medicines. The company focuses primarily on oncology, immunology, neurology and other specialty therapeutic areas, with an emphasis on discovering treatments for diseases with significant unmet medical needs.

Ono’s best-known product is Opdivo (nivolumab), an immuno-oncology medicine developed in collaboration with Bristol Myers Squibb and approved for multiple cancer indications in various markets. The company also markets and develops additional medicines through its own research programs and collaborations with global pharmaceutical and biotechnology companies.

Founded in Osaka in 1717 as a pharmaceutical wholesaler, Ono has evolved into a research-based drug manufacturer with operations and commercial activities in Japan and international markets. Its products are distributed globally through subsidiaries and strategic partnerships. The company is headquartered in Osaka, Japan, and is led by President and Chief Executive Officer Gyo Sagara.

View Ono Pharmaceutical Profile
Earnings Tools